Chester County News and Community Website
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) this week presented an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022). A copy of the …
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) recently presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La., …
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies …
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the European Patent Office recently issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism with Cannabidiol,” which …
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety (RECONNECT) Phase 3 trial.
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the Company has received guidance from the …
Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel Read More